- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06092112
A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma
The goal of this investigator-initiated, a single-arm, open-label, pilot study is to investigate the safety, tolerability, and efficacy of CD-801 treatment in subjects with advanced hepatocellular carcinoma.
Condition of disease: advanced hepatocellular carcinoma .
Intervention:treatment with 100μg CD-801 through the hepatic artery at two-week intervals. The dosing interval will be adjusted based on subject tolerability, safety, and efficacy. For example, it may be adjusted to administer the medication once every three weeks or four weeks.
Drug: CD-801, a drug designed specifically to enhance the expression of HNF4α and selectively target liver cancer cells.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Recent advancements in understanding tumor biology and the tumor microenvironment have dramatically transformed the treatment landscape for advanced stage HCC. However, the survival for advanced HCC patients still remains unsatisfactory.
Differentiation therapy in oncology is defined as a therapeutic strategy that reactivates endogenous differentiation programs and reverts malignant phenotypes. Its hallmark success is the treatment of acute promyelocytic leukemia (APL) by the combination of all-trans retinoic acid (ATRA) and arsenic. Unfortunately, this approach has achieved limited success in solid tumors.
Hepatocyte nuclear factor 4α (HNF4α) is a transcription factor (TF) belonging to the nuclear receptor family. HNF4α is highly enriched in mature hepatocytes and serves as a master regulator of hepatocyte differentiation and hepatic metabolism. Previous studies, including the investigators' and others, have demonstrated that the reduced expression of HNF4α plays a critical role in hepatocarcinogenesis. Restoring HNF4α expression induces the differentiation of HCC cells into mature hepatocytes and has shown significant therapeutic effects in various animal models of HCC.
In this study, the investigators developed CD-801, a drug designed specifically to enhance the expression of HNF4α and selectively target liver cancer cells, for the treatment of HCC patients. Preclinical studies have shown that CD-801 effectively inhibits the growth of subcutaneous and orthotopic liver tumors in mice. Acute toxicity tests in SD rats have demonstrated that a single intravenous injection of CD-801 injection at a dose of 150 μg/animal is well-tolerated, with no significant toxicity, indicating good safety profiles. Furthermore, in the dose escalation phase of the clinical trial which the investigators have completed, CD-801(25, 50 and 100 μg) was found to be well-tolerated. None of the patients experienced dose-limiting toxicities (DLTs) during the DLT phase.
This trial is a single-arm, open-label, exploratory clinical study aimed at further evaluating the efficacy, safety, and tolerability of 100 μg CD-801 administered through the hepatic artery in the treatment of advanced-stage HCC at two-week intervals (The dosing interval will be adjusted based on subject tolerability, safety, and efficacy. For example, it may be adjusted to administer the medication once every three weeks or four weeks).
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Chuan Yin, M.D.
- Phone Number: +8613482705212
- Email: ilse1225@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males or females, aged 18 years or older.
- Subjects must have confirmed diagnosis of HCC according to the American Association for the Study of Liver Diseases criteria.
- Unresectable HCC.
- Subjects are unsuitable for local or systemic anti-tumor therapy or had tumor progression after receiving at least one kind of conventional treatment.
- According to mRECIST, subjects should be with at least 1 measurable target lesion.
- Life expectancy of 12 weeks or more.
- Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2.
- Male with fertility and females of childbearing potential are willing to use a highly effective method of contraception for the entire study period and for 6 months after study drug discontinuation. Females of childbearing age, including premenopausal females and within 2 years after menopause, must have a negative serum pregnancy test result within 7 days prior to the first dose of study treatment.
- Subjects who have voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol.
Exclusion Criteria:
- ALB < 28 g/L, or Bilirubin >5.0 mg/dL, or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or alanine aminotransferase (ALT) >5×ULN.
- Inadequate renal function defined as creatinine >1.5 times the upper limit of normal (ULN) or calculated creatinine clearance < 40 mL/min.
- Absolute neutrophil count (ANC) < 1.0×109/L, or Platelets < 30×109/L, or Hemoglobin < 8.5 g/dL.
- International Normalized Ratio (INR) > 2.3.
- Subjects with a history of liver transplantation.
- Subjects with poorly controlled hypertension, diabetes or other serious heart or lung diseases, or with serious dysfunction.
- Subjects with extrahepatic metastasis who had potential benefit from first-line systemic therapies.
- Subjects who had prior anticancer treatment with any locoregional therapies, antiangiogenic targeted therapies, immune checkpoint inhibitors or chemotherapy within 4 weeks (within 2 weeks in case of sorafenib), radiotherapy within 3 weeks, or active traditional Chinese medicine within 2 weeks before the first dose of study treatment, except for the treatments after which the disease still progressed according to mRECIST.
- All toxicities related to prior locoregional or systemic anti-tumor treatments are still grade 2 or more (except for hair loss and other events that have been judged tolerable by researchers).
- Subjects with complication histories of liver cirrhosis or HCC such as gastrointestinal hemorrhage, overt hepatic encephalopathy, or uncontrollable ascites within 2 weeks prior to the first dose of study treatment.
- Uncontrolled active infection (eg, lung infections, or abdominal infections).
- Subjects with moderate to severe hepatic artery- portal vein fistula or hepatic artery - vein fistula which could not be avoided even through the artery super selection by DSA.
- History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%), such as adequately treated early gastric carcinoma, carcinoma in situ of the cervix, non-melanoma skin carcinoma, or localized prostate cancer.
- HBV DNA greater than 500 copies/mL, or HCV RNA greater than 15 U/mL.
- Subject is positive for Human Immunodeficiency Virus (HIV).
- Any subject who is allergic to MRI contrast agents.
- Pregnant/lactating women, or women who have the possibility of pregnancy.
- Participation in other investigational drug trials within 4 weeks prior to initiation of this study treatment.
- Any medical or other condition which, in the opinion of the investigator, would preclude participation in this clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CD-801 treatment
The subjects with advanced HCC will be treated by CD-801 through the hepatic artery injection.
|
The subjects with advanced HCC will be treated by 100 μg CD-801 through the hepatic artery injection at two-week intervals.
The dosing interval will be adjusted based on subject tolerability, safety, and efficacy.
For example, it may be adjusted to administer the medication once every three weeks or four weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The objective response rate based on mRECIST
Time Frame: From the first study dose date until the date of documented complete response or partial response, assessed up to 24 months
|
To assess the proportion of subjects who have best overall response of complete response or partial response at the time of data cutoff based on mRECIST
|
From the first study dose date until the date of documented complete response or partial response, assessed up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events as assessed by CTCAE v5.0
Time Frame: Through study completion, an average of 2 years
|
To assess the incidence and severity of AE after CD-801 treatment in subjects with advanced hepatocellular carcinoma by CTCAE v5.0
|
Through study completion, an average of 2 years
|
The objective response rate based on RECIST v1.1
Time Frame: From the first study dose date until the date of documented complete response or partial response, assessed up to 24 months
|
To assess the proportion of subjects who have best overall response of complete response or partial response at the time of data cutoff based on RECIST v1.1
|
From the first study dose date until the date of documented complete response or partial response, assessed up to 24 months
|
Duration of response based on mRECIST and RECIST v1.1
Time Frame: up to 24 months
|
To assess the time from the first documentation of complete response or partial response to the date of first documentation of disease progression or death (whichever occurs first) based on mRECIST and RECIST v1.1
|
up to 24 months
|
Progression-free survival based on mRECIST and RECIST v1.1
Time Frame: up to 24 months
|
To assess the time from the first study dose date to the date of first documentation of disease progression or death (whichever occurs first) based on mRECIST and RECIST v1.1
|
up to 24 months
|
Time to progression based on mRECIST and RECIST v1.1
Time Frame: up to 24 months
|
To assess the time from the first study dose date to the date of first documentation of disease progression based on mRECIST and RECIST v1.1
|
up to 24 months
|
Time to response based on mRECIST and RECIST v1.1
Time Frame: up to 24 months
|
To assess the time from the date of first study dose to the date of first documentation of complete response or partial response based on mRECIST and RECIST v1.1
|
up to 24 months
|
Disease control rate based on mRECIST and RECIST v1.1
Time Frame: up to 24 months
|
To assess the proportion of subjects who have best overall response of complete response or partial response or stable disease (minimum duration from C1D1 to stable disease ≥5 weeks) based on mRECIST and RECIST v1.1
|
up to 24 months
|
Clinical benefit rate based on mRECIST and RECIST v1.1
Time Frame: up to 24 months
|
To assess the proportion of subjects who have best overall response of complete response or partial response or durable stable disease (duration of stable disease ≥ 23 weeks) based on mRECIST and RECIST v1.1
|
up to 24 months
|
Overall Survival
Time Frame: Throughout the entire course of treatment until the end of the follow-up period, an average of 2 years
|
To assess the time from the first study dose date until date of death from any cause .
Subjects who are lost to follow-up and the subjects who are alive at the date of data cutoff will be censored at the date the subject was last known alive or the cut-off date, whichever comes earlier.
|
Throughout the entire course of treatment until the end of the follow-up period, an average of 2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health Related Quality of Life based on the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30.
Time Frame: Through study completion, an average of 2 years
|
To evaluate the impact of CD-801 treatment on Health Related Quality of Life for subjects treated using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30.
|
Through study completion, an average of 2 years
|
Health Related Quality of Life based on HCC-specific EORTC QLQ-HCC18 questionnaire.
Time Frame: Through study completion, an average of 2 years
|
To evaluate the impact of CD-801 treatment on Health Related Quality of Life for subjects treated using HCC-specific EORTC QLQ-HCC18 questionnaire.
|
Through study completion, an average of 2 years
|
Health Related Quality of Life based on European Quality of Life questionnaire.
Time Frame: Through study completion, an average of 2 years
|
To evaluate the impact of CD-801 treatment on Health Related Quality of Life for subjects treated using European Quality of Life questionnaire.
|
Through study completion, an average of 2 years
|
The impact of CD-801 treatment on cytokine in serum after treatment.
Time Frame: Through study completion, an average of 2 years
|
To investigate the changes of cytokine in serum in subjects with advanced hepatocellular carcinoma after CD-801 treatment
|
Through study completion, an average of 2 years
|
The impact of CD-801 treatment on immune cell profiling in serum after treatment.
Time Frame: Through study completion, an average of 2 years
|
To investigate the changes of immune cell profiling in serum in subjects with advanced hepatocellular carcinoma after CD-801 treatment
|
Through study completion, an average of 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wei-Fen Xie, M.D., Shanghai Changzheng Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CZXH-HCC-2023-IIT-EX
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Hepatocellular Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterMerck Sharp & Dohme LLC; Highlight TherapeuticsTerminatedAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Refractory Hepatocellular CarcinomaUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
The University of Hong KongUnknownAdvanced Hepatocellular Carcinoma | Metastatic Hepatocellular CarcinomaChina
-
Mayo ClinicRecruitingAdvanced Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8United States
-
AmgenCompletedAdvanced Hepatocellular Carcinoma | Inoperable Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnUnresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
-
University of WashingtonExelixisTerminatedAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular CarcinomaUnited States
Clinical Trials on CD-801
-
Maastricht University Medical CenterWinclove Bio Industries BVCompletedHypersensitivity | Irritable Bowel SyndromeNetherlands
-
Oncolys BioPharma IncUnknown
-
Alzheon Inc.Quotient ClinicalCompletedAlzheimer Disease
-
Alzheon Inc.Active, not recruitingEarly Alzheimer's DiseaseNetherlands, Czechia
-
Altimmune, Inc.Completed
-
Stemline Therapeutics, Inc.CompletedSolid TumorsUnited States
-
Alzheon Inc.Not yet recruitingEarly Alzheimer's DiseaseUnited States, Canada, United Kingdom
-
Michael Rapoff, Ph.D.National Institute of Neurological Disorders and Stroke (NINDS)Completed
-
Oscotec Inc.PPDCompletedAcute Myeloid LeukemiaUnited States
-
Altimmune, Inc.CompletedType 2 DiabetesUnited States